From the Clinic of Nuclear Medicine.
Pathology Section, Institute of Forensic Medicine, Jena University Hospital, Jena, Germany.
Clin Nucl Med. 2023 Dec 1;48(12):1049-1050. doi: 10.1097/RLU.0000000000004879. Epub 2023 Oct 5.
A 64-year-old man with metastatic castration-resistant prostate cancer presented for prostate-specific membrane antigen (PSMA) PET/CT in preparation for 177 Lu-PSMA radioligand therapy. For precedent BRCA mutation assessment, fine-needle aspiration cytology of 2 PSMA-positive lymph node metastases was conducted. The acquired material was suitable for next-generation sequencing-based gene panel diagnostics and did not show a BRCA1 / 2 mutation, thus PSMA radioligand therapy was initiated. Fine-needle aspiration cytology of lymph node metastases may be a viable option in evaluating further therapeutic alternatives.
一位 64 岁患有转移性去势抵抗性前列腺癌的男性，为了准备接受 177Lu-PSMA 放射性配体治疗，进行了前列腺特异性膜抗原（PSMA）PET/CT。为了进行先前的 BRCA 突变评估，对 2 个 PSMA 阳性的淋巴结转移进行了细针穿刺细胞学检查。获得的材料适合基于下一代测序的基因面板诊断，未显示 BRCA1/2 突变，因此开始了 PSMA 放射性配体治疗。对淋巴结转移进行细针穿刺细胞学检查可能是评估其他治疗选择的可行选择。
